Reshma Mahtani

15PUBLICATIONS
82CO-AUTHORS
Predictive and prognostic markersEconomic models and forecastingCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jun 24, 2026
Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.

|Nov 14, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Hope S Rugo, Virginia Kaklamani, Heather McArthur

|Aug 25, 2025
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.

Lorenzo Gerratana, Carolina Reduzzi, Yue Ren

|Nov 21, 2024
Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases.

Vaseem M Khatri, Mariella A Mestres-Villanueva, Sreenija Yarlagadda

|Mar 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.

Erica L Mayer, Yue Ren, Nikhil Wagle

|Jul 10, 2023
Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?

Naomi Dempsey, Ana Sandoval, Reshma Mahtani

Pageof 3

Frequent Collaborators

3 joint publications

Sara M Tolaney

2 joint publications

Sonya Reid

2 joint publications

Eric Gauthier

2 joint publications

Priyanka Sharma